Nektar Therapeutics (LTS:0UNL) Total Liabilities : $269.31 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Total Liabilities?

Nektar Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $269.31 Mil.

Nektar Therapeutics's quarterly Total Liabilities declined from Sep. 2023 ($282.88 Mil) to Dec. 2023 ($267.05 Mil) but then increased from Dec. 2023 ($267.05 Mil) to Mar. 2024 ($269.31 Mil).

Nektar Therapeutics's annual Total Liabilities declined from Dec. 2021 ($437.68 Mil) to Dec. 2022 ($343.96 Mil) and declined from Dec. 2022 ($343.96 Mil) to Dec. 2023 ($267.05 Mil).

Nektar Therapeutics Total Liabilities Historical Data

The historical data trend for Nektar Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Total Liabilities Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

571.97

461.47

437.68

343.96

267.05

Nektar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															320.88	297.32	282.88	267.05	269.31

Nektar Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nektar Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	51.269	+	(98.517	+	117.26
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	267.05

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	398.033	-	130.987
	=	267.05

Nektar Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	52.406	+	(94.71	+	122.191
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	269.31

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	396.012	-	126.705
	=	269.31

Nektar Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (LTS:0UNL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NKTR:USA ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (LTS:0UNL) Headlines

No Headlines